Department of Medicinal Radiochemistry
The department of Medicinal Radiochemistry focusses on the development and biological evaluation of radioligands for imaging and therapy of cancer. The cellular and molecular components of the tumor microenvironment (TME) represent interesting targets for imaging and therapy of tumor entities. In order to address these targets, medicinal chemistry techniques for developing new tumor vectors (Small organic molecules, peptides and antibody fragments) as well as the development of new chelators and the biological evaluation in cell and animal models are applied.
The receptors within the TME can serve as imaging biomarkers for the early detection of tumor diseases and for monitoring the treatment response, but also as target structures for endoradiotherapy using alpha and beta emitters. As part of the theranostic concept, matched pairs of radionuclides are used, consisting of positron or gamma emitters on the one hand and beta emitters on the other, in order to enable both imaging and therapy of tumors with the same target vector.
Based on the application of the diagnostic radionuclide an individualized patient-specific internal radiation dose can be predicted precisely and then applied by directed internal irradiation using the corresponding therapeutic radionuclide either alone or in combination with external beam irradiation or other therapeutic approaches including chemo- or immunotherapy.
The strategic goal is the translation of the developed radioligands into the clinic as a diagnostic tool, e.g. to enable and optimize patient stratification, and for nuclear medicine therapy of cancer
- Small molecule and peptide-based radiotracer
- Preclinical Radioconjugates
- Therapeutic Alpha Emitters
- Multi-targeted Radiotheranostics
- Radiometal-based bioconjugates
Applications for PhD, Master and Bachelor thesis as well as research internships from chemists, biochemists, pharmaceutical/ medicinal chemists and other fields are always welcome.